Osteopontin - A promising biomarker for cancer therapy

Journal of Cancer

Volumn 8, Issue 12, 2017, Pages 2173-2183

  Wei, Ran ^a   Wong, Janet Pik Ching ^a   Kwok, Hang Fai ^a  

^a University of Macau   (Macao)

Author keywords

Angiogenesis; Biomarker; Osteopontin; Therapeutic target; Tumor biology

Indexed keywords

HERMES ANTIGEN; OSTEOPONTIN;

BIOMINERALIZATION; BONE REMODELING; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CELLULAR IMMUNITY; COLORECTAL CANCER; HUMAN; LIVER CELL CARCINOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; STOMACH CANCER; TISSUE DISTRIBUTION; WOUND HEALING;

EID: 85025481550     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.20480     Document Type: Review

References (101)

1. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS: The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006, 17(6):463-474.
2. Senger DR, Wirth DF, Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979, 16(4):885-893.
3. Pagel CN, Wijesinghe DKW, Esfandouni NT, Mackie EJ: Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle. J cell Commun Signal 2014, 8(2):95-103.
4. Giachelli CM, Steitz S: Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000, 19(7):615-622.
5. Lund SA, Giachelli CM, Scatena M: The role of osteopontin in inflammatory processes. J cell Commun Signal 2009, 3(3-4):311-322.
6. Wai PY, Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008, 27(1):103-118.
7. Fisher L, Torchia D, Fohr B, Young M, Fedarko N: Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001, 280(2):460-465.
8. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001, 7(12):4060-4066.
9. Yang X, Yan W, Tian Y, Ma P, Opperman LA, Wang X: Family with sequence similarity member 20C is the primary but not the only kinase for the small-integrin-binding ligand N-linked glycoproteins in bone. FASEB J 2015, 30(1):121-128
10. Fisher LW, Jain A, Tayback M, Fedarko NS: Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 2004, 10(24):8501-8511.
11. Shinohara ML, Kim HJ, Kim JH, Garcia VA, Cantor H: Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci 2008, 105(20):7235-7239.
12. El-Tanani MK: Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci 2008, 13:4276-4284.
13. Denhardt DT, Guo X: Osteopontin: a protein with diverse functions. FASEB J 1993, 7(15):1475-1482.
14. Cao D, Li Z, Jiang X, Lum YL, Khin E, Lee NP, Wu G, Luk JM: Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012, 18(30):3923.
15. O'Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson JB, Schwartz SM, Giachelli CM: Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994, 14(10):1648-1656.
16. Malyankar UM, Almeida M, Johnson RJ, Pichler RH, Giachelli CM: Osteopontin regulation in cultured rat renal epithelial cells. Kidney Int 1997, 51(6):1766-1773.
17. Craig AM, Denhardt DT: The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene 1991, 100:163-171.
18. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y, Moylan C, Jung Y, Bhattacharya SD, Teaberry V, Omenetti A, Abdelmalek MF, Guy CD, Adams DH, Kuo PC, Michelotti GA, Whitington PF, Diehl AM: Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011, 53(1):106-115.
19. Iwamoto DV, Calderwood DA: Regulation of integrin-mediated adhesions. Curr Opin Cell Biol 2015, 36:41-47.
20. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS: Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107(9):1055-1061.
21. Chen Q, Shou P, Zhang L, Xu C, Zheng C, Han Y, Li W, Huang Y, Zhang X, Shao C: An Osteopontin-Integrin Interaction Plays a Critical Role in Directing Adipogenesis and Osteogenesis by Mesenchymal Stem Cells. Stem Cells 2014, 32(2):327-337.
22. Zhang H, Guo M, Chen JH, Wang Z, Du XF, Liu PX, Li WH: Osteopontin knockdown inhibits alphav, beta3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/mTOR pathway. Cell Physiol Biochem 2014, 33(4):991-1002.
23. Dalal S, Zha Q, Daniels CR, Steagall RJ, Joyner WL, Gadeau AP, Singh M, Singh K: Osteopontin stimulates apoptosis in adult cardiac myocytes via the involvement of CD44 receptors, mitochondrial death pathway, and endoplasmic reticulum stress. Am J Physiol Heart Circ Physiol 2014, 306(8):H1182-91.
24. Stemberger C, Matusan-Ilijas K, Avirovic M, Bulat-Kardum L, Ivancic A, Jonjic N, Lucin K: Osteopontin is associated with decreased apoptosis and alphav integrin expression in lung adenocarcinoma. Acta Histochem 2014, 116(1):222-229.
25. Zou C, Luo Q, Qin J, Shi Y, Yang L, Ju B, Song G: Osteopontin promotes mesenchymal stem cell migration and lessens cell stiffness via integrin beta1, FAK, and ERK pathways. Cell Biochem Biophys 2013, 65(3):455-462.
26. Behera R, Kumar V, Lohite K, Karnik S, Kundu GC: Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis 2010, 31(2):192-200.
27. Hui T, Sørensen ES, Rittling SR: Osteopontin binding to the alpha 4 integrin requires highest affinity integrin conformation, but is independent of post-translational modifications of osteopontin. Matrix Biol 2015, 41:19-25.
28. Grassinger J, Haylock DN, Storan MJ, Haines GO, Williams B, Whitty GA, Vinson AR, Be CL, Li S, Sorensen ES, Tam PP, Denhardt DT, Sheppard D, Choong PF, Nilsson SK: Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood 2009, 114(1):49-59.
29. Kale S, Raja R, Thorat D, Soundararajan G, Patil T, Kundu G: Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via a9ß1 integrin. Oncogene 2014, 33(18):2295-2306.
30. Denhardt DT, Guo X: Osteopontin: a protein with diverse functions. FASEB J 1993, 7(15):1475-1482.
31. Trapasso S, Garozzo A, Belfiore A, Allegra E: Evaluation of the CD44 isoform v-6 (sCD44var, v6) in the saliva of patients with laryngeal carcinoma and its prognostic role. Cancer Biomark 2016, 16(2):275-280.
32. Rao G, Wang H, Li B, Huang L, Xue D, Wang X, Jin H, Wang J, Zhu Y, Lu Y, Du L, Chen Q: Reciprocal interactions between tumor-associated macrophages and CD44-positive cancer cells via osteopontin/CD44 promote tumorigenicity in colorectal cancer. Clin Cancer Res 2013, 19(4):785-797.
33. Zhang GX, Zhao ZQ, Wang HD, Hao B: Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway. World J Gastroenterol 2004, 10(2):205-208.
34. Gauer S, Hauser IA, Obermuller N, Holzmann Y, Geiger H, Goppelt-Struebe M: Synergistic induction of osteopontin by aldosterone and inflammatory cytokines in mesangial cells. J Cell Biochem 2008, 103(2):615-623.
35. Noda M, Yoon K, Prince CW, Butler WT, Rodan GA: Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. J Biol Chem 1988, 263(27):13916-13921.
36. Noda M, Rodan GA: Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J Cell Biol 1989, 108(2):713-718.
37. Gericke A, Qin C, Spevak L, Fujimoto Y, Butler WT, Sørensen ES, Boskey AL: Importance of Phosphorylation for Osteopontin Regulation of Biomineralization. Calcif Tissue Int 2005, 77(1):45-54.
38. Sodek J, Ganss B, McKee MD: Osteopontin. Crit Rev Oral Biol Med 2000, 11(3):279-303.
39. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J: Osteopontin-a molecule for all seasons. QJM 2002, 95(1):3.
40. Li X, O'Regan AW, Berman JS: IFN-γ induction of osteopontin expression in human monocytoid cells. J Interferon Cytokine Res 2003, 23(5):259-265.
41. Dey NB, Boerth NJ, Murphy-Ullrich JE, Chang PL, Prince CW, Lincoln TM: Cyclic GMP-dependent protein kinase inhibits osteopontin and thrombospondin production in rat aortic smooth muscle cells. Circ Res 1998, 82(2):139-146.
42. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, Giachelli CM: Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002, 161(6):2035-2046.
43. Scatena M, Liaw L, Giachelli CM: Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007, 27(11):2302-2309.
44. Kitahara K, Ishijima M, Rittling SR, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M: Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation. Endocrinology 2003, 144(5):2132-2140.
45. Wang KX, Denhardt DT: Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008, 19(5):333-345.
46. Miyazaki K, Okada Y, Yamanaka O, Kitano A, Ikeda K, Kon S, Uede T, Rittling SR, Denhardt DT, Kao WW, Saika S: Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci 2008, 49(4):1367-1375.
47. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL: Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998, 101(7):1468-1478.
48. Miragliotta V, Pirone A, Donadio E, Abramo F, Ricciardi MP, Theoret CL: Osteopontin expression in healing wounds of horses and in human keloids. Equine Vet J 2016, 48(1):72-77.
49. Chatterjee SK, Zetter BR: Cancer biomarkers: knowing the present and predicting the future. Future Oncology 2005, 1(1): 37-50.
50. Mishra A, Verma M: Cancer biomarkers: are we ready for the prime time? Cancers 2010, 2(1):190-208.
51. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of a-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19(1):61-66.
52. Lindblom A, Liljegren A: Regular review: tumour markers in malignancies. BMJ 2000, 320(7232):424-427.
53. Lamberts SWJ, Hofland LJ, Nobels FRE, Lamberts SWJ, Hofland LJ, Nobels FRE: Neuroendocrine Tumor Markers. Front Neuroendocrinol 2001, 22(4):309-339.
54. Gendler SJ, Burchell JM, Duhig T, Lamport D, White R, Parker M, Taylor-Papadimitriou J: Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci 1987, 84(17):6060-6064.
55. SafiF, Kohler I, Beger H, Röttinger E: The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991, 68(3):574-582.
56. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas J: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BJOG: An International Journal of Obstetrics & Gynaecology 1990, 97(10):922-929.
57. Hu Z, Wei T, Yang M, Ma N, Tang Q, Qin B, Fu H, Zhong R: Diagnostic Value of Osteopontin in Ovarian Cancer: A Meta-Analysis and Systematic Review. PLoS ONE 2015, 10(5):e0126444.
58. Subraman V, Thiyagarajan M, Malathi N, Rajan ST: OPN-Revisited. JCDR 2015, 9(6):10.
59. Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, Yau TC, Lo O, Foo C, Poon JT, Poon RT, Pang R, Law W: Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer. Stem Cells Int 2015, 2015:1-8.
60. Weber GF, Lett GS, Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010, 103(6):861.
61. Weber GF: The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics 2011, 8(6):263-288.
62. Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, Viola JP, Weber GF, Gimba ER: Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 2011, 9(3):280-293.
63. Phillips RJ, Helbig KJ, Van der Hoek, Kylie H, Seth D, Beard MR: Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol 2012, 18(26):3389-3399.
64. Lin J, Myers AL, Wang Z, Nancarrow DJ, Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang TD, Orringer MB, Reddy RM, Chang AC, Beer DG, Lin L: Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget 2015, 6(26):22239-22257.
65. Butti R, Ghosh P, Totakura KV, Venkata RNN, Nimma R, Kundu GC: Role of Osteopontin in Tumor Microenvironment: A New Paradigm in Cancer Therapy. In Multi-Targeted Approach to Treatment of Cancer. Edited by Anonymous Springer; 2015:113-125.
66. Wai PY, Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008, 27(1):103-118.
67. Likui W, Hong W, Shuwen Z, Yuangang Y, Yan W: The potential of osteopontin as a therapeutic target for human colorectal cancer. J Gastrointest Surg 2011, 15(4):652-659.
68. Ng L, Wan TM, Lam CS, Chow AK, Wong SK, Man JH, Li H, Cheng NS, Pak RC, Cheung AH, Yau TC, Lo OS, Foo DC, Poon JT, Poon RT, Pang RW, Law W: Post-Operative Plasma Osteopontin Predicts Distant Metastasis in Human Colorectal Cancer. PLoS ONE 2015, 10(5):e0126219.
69. Shevde LA, Samant RS: Mini review: Role of osteopontin in the pathophysiology of cancer. Matrix Biol 2014, 37:131-141.
70. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G: CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 2014, 14(3):342-356.
71. Sun B, Dong Q, Ye Q, Sun H, Jia H, Zhu X, Liu D, Chen J, Xue Q, Zhou H: Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008, 48(6):1834-1842.
72. Steinman L: A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 2009, 9(6):440-447.
73. Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, Mane A, Karnik S, Kundu G: Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1a-mediated VEGF-dependent angiogenesis. Oncogene 2014, 33(16):2053-2064.
74. Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M, Kundu GC: Functional characterization of stromal osteopontin in melanoma progression and metastasis. PloS ONE 2013, 8(7):e69116.
75. Bandopadhyay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P, Ghosh P, Gorain M, Kale S, Kumar D, Kumar S, Totakura KV, Roy G, Sharma P, Shetti D, Soundararajan G, Thorat D, Tomar D, Nalukurthi R, Raja R, Mishra R, Yadav AS, Kundu GC: Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets 2014, 18(8):883-895.
76. Sharon Y, Raz Y, Cohen N, Ben-Shmuel A, Schwartz H, Geiger T, Erez N: Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res 2015, 75(6):963-973.
77. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M: Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004, 13(3):487-491.
78. Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo C, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER: Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol 2012, 92:13-19.
79. Nakamura T, Shinriki S, Jono H, Ueda M, Nagata M, Guo J, Hayashi M, Yoshida R, Ota T, Ota K, Kawahara K, Nakagawa Y, Yamashita S, Nakayama H, Hiraki A, Shinohara M, Ando Y: Osteopontin-integrin avß3 axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma. FEBS Lett 2015, 589(2):231-239.
80. Liu J, Liu Q, Wan Y, Zhao Z, Yu H, Luo H, Tang Z: Osteopontin promotes the progression of gastric cancer through the NF-kappaB pathway regulated by the MAPK and PI3K. Int J Oncol 2014, 45(1):282-290.
81. Matsuura M, Suzuki T, Saito T: Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci 2010, 101(8):1828-1833.
82. Srungaram P, Rule JA, Yuan HJ, Reimold A, Dahl B, Sanders C, Lee WM: Plasma osteopontin in acute liver failure. Cytokine 2015, 73:270-276.
83. Sun B, Li Y, Zhang Z, You J, Wang C: Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 2013, 96(6):1943-1951.
84. Zhu W, Guo L, Zhang B, Lou L, Lin Z, Zhu X, Ren N, Dong Q, Ye Q, Qin L: Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection. Ann Surg Oncol 2014, 21(4):1304-1313.
85. Ramchandani D, Weber GF: Interactions between osteopontin and vascular endothelial growth factor: implications for cancer. BBA-Reviews on Cancer 2015, 1855(2):202-222.
86. Chang-Ni Lin, Chih-Jung Wang, Ying-Jui Chao, Ming-Derg Lai, Yan-Shen Shan: The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression. BMC Cancer 2015, 15(1):1.
87. Lan Z, Fu D, Yu X, Xi M: Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis. Fam Cancer 2016, 15(2): 221-230.
88. Wu Y, Denhardt DT, Rittling SR: Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 2000, 83(2):156-163.
89. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT, Noda M: Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 2001, 16(4):652-659.
90. Wu XL, Lin KJ, Bai AP, Wang WX, Meng XK, Su XL, Hou MX, Dong PD, Zhang JJ, Wang ZY, Shi L: Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells. World J Gastroenterol 2014, 20(30):10440-10448.
91. Yang L, Zhao W, Zuo WS, Wei L, Song XR, Wang XW, Zheng G, Zheng MZ: Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor. Chin Med J (Engl) 2012, 125(2):293-299.
92. Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC: Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011, 32(4):477-487.
93. Mi Z, Guo H, Wai PY, Gao C, Kuo PC: Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 2006, 27(6):1134-1145.
94. Kumar S, S Patil H, Sharma P, Kumar D, Dasari S, G Puranik V, V Thulasiram H, C Kundu G: Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway. Curr Mol Med 2012, 12(8):952-966.
95. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC: RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009, 17(1):153-161.
96. Rupaimoole R, Slack FJ: MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 2017, 16(3):203-222.
97. Shevde LA, Metge BJ, Mitra A, Xi Y, Ju J, King JA, Samant RS: Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. J Cell Mol Med 2010, 14(6b):1693-1706.
98. Bhattacharya SD, Garrison J, Guo H, Mi Z, Markovic J, Kim VM, Kuo PC: Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. Surgery 2010, 148(2):291-297.
99. Petrocca F, Lieberman J: Micromanipulating cancer: microRNA-based therapeutics? RNA Biology 2009, 6(3):335-340.
100. Cao D, Li Z, Jiang X, Lum YL, Khin E, Lee NP, Wu G, Luk JM: Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012, 18(30):3923-3930.
101. Tu M, Li Y, Zeng C, Deng Z, Gao S, Xiao W, Luo W, Jiang W, Li L, Lei G: MicroRNA-127-5p regulates osteopontin expression and osteopontin-mediated proliferation of human chondrocytes. Sci Rep 2016, 6:25032.